



3-1-06

1623/IFe

Express mail No.: EQ 225 775 988 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Christopher B. Wood *et al.*

Confirmation No.: 6163

Serial No.: 10/529,519

Art Unit: To be Assigned

Filed: March 25, 2005

Examiner: To be Assigned

For: METHODS AND COMPOSITIONS FOR THE
TREATMENT OF AUTOIMMUNE
DISORDERS USING CLOFARABINEAttorney Docket No.: 10103-015-999
(CAM:) (052922-999015)

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure provisions of 37 C.F.R. §1.56, there is hereby provided certain information which the Examiner may consider material to the examination of the subject U.S. patent application. It is requested that the Examiner make this information of record if it is deemed material to the examination of the application.

1. Enclosures accompanying this Information Disclosure Statement are:

1a. ☒ A list of all patents, publications, applications, or other information submitted for consideration by the office.

1b. A legible copy of:

☒ Each U.S. patent and foreign patent. Pursuant to 37 CFR 1.98(a)(2) as amended (Federal Register, vol. 69, No.182, September 21, 2004, p.56510), copies of U.S. patents are not submitted herewith;☒ Each publication or that portion which caused it to be listed on the PTO-1449;☐ For each cited pending U.S. application, the application specification including the claims, and any drawing of the application, or portion of the application which caused it to be listed on the PTO-1449 including any claims directed to that portion;☒ all other information or portion which caused it to be listed on the PTO-1449.1c. ☐ An English language copy of search report(s) from a counterpart foreign application or PCT International Search Report.1d. ☐ Explanations of relevancy (ATTACHMENT 1(d), hereto) or English language abstracts of the non-English language publications.2. ☒ This Information Disclosure Statement is filed under 37 C.F.R. §1.97(b):☐ Within three months of the filing date of a national application other than a continued prosecution application under §1.53(d);☐ Within three months of the date of entry of the national stage as set forth in §1.491 in

an international application;

- ☒ Before the mailing of the first Office action on the merits;
- ☐ Before the mailing of a first Office action after the filing of a request for continued examination under §1.114.

3. ☐ This Information Disclosure Statement is filed under 37 C.F.R. §1.97(c) after the period specified in 37 C.F.R. §1.97(b), but before the mailing date of any of a final action under 37 C.F.R. §1.113, a notice of allowance under 37 C.F.R. §1.311 or an action that otherwise closes prosecution in the application.

(Check either Item 3a or 3b)

- 3a. ☐ The Certification Statement in Item 5 below is applicable. Accordingly, no fee is required.
- 3b. ☐ The \$180.00 fee set forth in 37 C.F.R. §1.17(p) in accordance with 37 C.F.R. §1.97(c) is:
- ☐ enclosed
- ☐ to be charged to Jones Day Deposit Account No. 50-3013.

(Item 3b to be checked if any reference known for more than 3 months)

4. ☐ This Information Disclosure Statement is filed under 37 C.F.R. §1.97(d) after the period specified in 37 C.F.R. §1.97(c), but on or before the date of payment of the issue fee.

The Certification Statement in Item 5 below is applicable.

The \$180.00 fee set forth in 37 C.F.R. §1.17(p) is:

- ☐ enclosed.
- ☐ to be charged to Jones Day Deposit Account No. 50-3013

5. ☐ Certification Statement (applicable if Item 3a or Item 4 is checked)

(Check either Item 5a or 5b)

- 5a. ☐ In accordance with 37 C.F.R. §1.97(e)(1), it is certified that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.
- 5b. ☐ Each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart application, and the communication was not **received** by any individual designated in 37 C.F.R. §1.56(c) more than thirty days prior to the filing of this information disclosure statement.
- 5c. ☐ Pursuant to 37 C.F.R. §1.704(d), each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart application, and the communication was not **received** by any individual designated in 37 C.F.R. §1.56(c) more than thirty days prior to the filing of this information disclosure statement.

6. ☐ This application is a continuation application under 37 C.F.R. §1.60 or §1.53(b) or (d).

(Check appropriate Items 6a, 6b and/or 6c)

- 6a. ☐ A Petition to Withdraw from issue under 37 C.F.R. §1.313(b)(5) is concurrently filed herewith.
- 6b. ☐ Copies of publications listed on Form PTO-1449 from prior application Serial No. _____, filed on _____, of which this application claims priority under 35 U.S.C. §120, are not being submitted pursuant to 37 C.F.R. §1.98(d).
- 6c. ☐ Copies of the publications listed on Form PTO-1449 were not previously cited in prior application Serial No. _____, filed on _____, and are provided herewith.

7. ☐ This is a Supplemental Information Disclosure Statement.

- 7a. ☐ This Supplemental Information Disclosure Statement under 37 C.F.R. §1.97(f) supplements the Information Disclosure Statement filed on _____. A bona fide attempt was made to comply with 37 C.F.R. §1.98, but inadvertent omissions were made. These omissions have been corrected herein. Accordingly, additional time is requested so that this Supplemental Information Disclosure Statement can be considered as if properly filed on _____.


8. ☐ In accordance with 37 C.F.R. §1.98, a concise explanation of what is presently understood to be the relevance of each non-English language publication is:

(Check Item 8a, 8b, or 8c)


- 8a. ☐ satisfied because all non-English language publications were cited on the enclosed English language copy of the PCT International Search Report or the search report from a counterpart foreign application indicating the degree of relevance found by the foreign office.
- 8b. ☐ set forth in the application.
- 8c. ☐ enclosed as an attachment hereto.
9. ☒ The Commissioner is authorized to charge any additional fee required or credit any overpayment for this Information Disclosure Statement and/or Petition to Jones Day Deposit Account No. 50-3013.
10. ☒ No admission is made that the information cited in this Statement is, or is considered to be, material to patentability nor a representation that a search has been made (other than a search report of a foreign counterpart application or PCT International Search Report if submitted herewith). 37 C.F.R. §§1.97(g) and (h).

Respectfully submitted,

Date: February 27, 2006


for Lawrence S. Graham Reg. No. 49,020
Anthony M. Insogna Reg. No. 35,203

JONES DAY
222 East 41st Street
New York, New York 10017
(212) 326-3939

**LIST OF REFERENCES CITED BY APPLICANT**
(Use several sheets if necessary)ATTY DOCKET NO.:
10103-015-999
(052922-999015)

APPLICATION NO.:

10/529,519

APPLICANT

Wood *et al.*

CONFIRMATION NO.:

6163

FILING DATE

March 25, 2005

ART UNIT:

To be Assigned

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A1	4,751,221	06/14/88	Watanabe <i>et al.</i>	514	46	
	A2	4,918,179	04/17/90	Watanabe <i>et al.</i>	536	27.4	
	A3	5,034,518	07/23/91	Montgomery <i>et al.</i>	536	27.4	
	A4	5,106,837	04/21/92	Carson <i>et al.</i>	514	46	
	A5	5,310,732	05/10/94	Carson <i>et al.</i>	514	46	
	A6	5,541,164	07/30/96	Carson <i>et al.</i>			
	A7	5,384,310	01/24/95	Montgomery <i>et al.</i>	514	46	
	A8	5,506,213	04/09/96	Carson <i>et al.</i>	514	46	
	A9	5,506,214	04/09/96	Beutler	514	46	
	A10	5,661,136	08/26/97	Montgomery <i>et al.</i>	514	46	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
							YES NO

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

	C1	Dahl <i>et al.</i> , Poster 527 at American Association of Cancer Research, San Francisco, CA, April 1-5, 2000
	C2	Engelke <i>et al.</i> , Poster 342 at American Association of Cancer Research, San Francisco, CA, April 1-5, 2000
	C3	Fowler <i>et al.</i> , <i>Nucleosides, Nucleotides, Nucleic Acids</i> 20(8)1583-1598 (2001)
	C4	Genini <i>et al.</i> , <i>Blood</i> 96:3537 (2000)
	C5	Johnson <i>Expert Opin Pharmacother</i> 2(6):929-943 (2001)

EXAMINER**DATE CONSIDERED**

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.